3.1 francois dabis
DESCRIPTION
TRANSCRIPT
![Page 1: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/1.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
1CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Tackling infectious diseases
French-based international research
networksFrançois Dabis
![Page 2: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/2.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Infectious diseases: 2/3 of all deaths in children <5 years
Black RE – Lancet 2010
18%
15%
31%
![Page 3: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/3.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
The French-based international infectious
diseases research networks
3
![Page 4: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/4.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
4 networks of excellenceactive in most of the developing world
![Page 5: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/5.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Respiratory Infections Encephalitis
HIV/AIDSHepatitisZoonosisDengueMalaria
Research toolsMicroorganism
cultureBiobank/Databank
SurveillanceCohorts
Entomology
Priority areasPublic health reference labs
ResearchTraining
Asia-Pacific Region
9 Institutes
![Page 6: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/6.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
The HIV/AIDS pandemic significant challenges
Pressing need to increase research efforts
in prevention and care 34 million of people living with HIV worldwide in 2010
2.6 million new HIV infections in 2010 only (7 000 / day)
1.4 million have started antiretroviral treatment in 2010
![Page 7: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/7.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
7
Low 4-year mortality on antiretroviral treatment is achievable in developing countries (Lancet 2006)
sub-Saharan Africa (ART-LINC)18 cohorts4,810 pts
Europe & North America (ART-CC)
Months after start of ART
0 12 24 36 48
Cum
ulat
ive
mor
talit
y (%
)
0
5
10
15
Risk of death (%)
![Page 8: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/8.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Lowering the risk of mother-to-child transmission of HIV in pregnant women
Côte d’Ivoire ANRS experience(Lancet 1999, AIDS 2005, PLoS Medicine 2007)
![Page 9: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/9.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
From animal modelto phase I/II
(safety, pk, viral resistance) in
Cambodia, Côte d’Ivoire and
South Africa
Prevention of Mother-to-Child Transmission of HIV
Antimicrob Agents Chemother 2009, 2011 a, b, c, dAIDS 2009, 2010Clin Pharmacol Ther 2009
![Page 10: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/10.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Antiretrovirals for the prevention of mother-to-child
transmission of HIVfrom phase I/II
toWHO guidelines
![Page 11: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/11.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Toward elimination of pediatric HIV
infection by 2015
![Page 12: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/12.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Perspectives
12
(1) Public/private investments from basic to translational research:
MultidisciplinaryUsing existing networksClassic and emerging pathogens
![Page 13: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/13.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Perspectives
13
(2) Public/private partnerships
should include phase IV and pharmaco-epidemiology
![Page 14: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/14.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
Perspectives
14
(3) A viable market
Deauville, May 26-27, 2011 (VI / 60)G8 encourages drug companies to work with
Medicines Patent Pool and welcomes the development of AMC
![Page 15: 3.1 francois dabis](https://reader033.vdocuments.us/reader033/viewer/2022061211/549287f0b479592f508b4579/html5/thumbnails/15.jpg)
CEA CHRU
CNRS CPU INRA
INRIA INSERM
INSTITUT PASTEUR
IRD
15